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Abstract
Background: Arsenic in drinking water, a major health hazard to millions of people
in South and East Asia and in other parts of the world, is ingested primarily as
trivalent inorganic arsenic (iAs), which then undergoes hepatic methylation to
methylarsonic acid (MMAs) and a second methylation to dimethylarsinic acid (DMAs).
Although MMAs and DMAs are also known to be toxic, DMAs is more easily excreted
in the urine and therefore methylation has generally been considered a
detoxification pathway. A collaborative modeling project between epidemiologists,
biologists, and mathematicians has the purpose of explaining existing data on
methylation in human studies in Bangladesh and also testing, by mathematical
modeling, effects of nutritional supplements that could increase As methylation.
Methods: We develop a whole body mathematical model of arsenic metabolism
including arsenic absorption, storage, methylation, and excretion. The parameters for
arsenic methylation in the liver were taken from the biochemical literature. The
transport parameters between compartments are largely unknown, so we adjust
them so that the model accurately predicts the urine excretion rates of time for the
iAs, MMAs, and DMAs in single dose experiments on human subjects.
Results: We test the model by showing that, with no changes in parameters, it
predicts accurately the time courses of urinary excretion in mutiple dose experiments
conducted on human subjects. Our main purpose is to use the model to study and
interpret the data on the effects of folate supplementation on arsenic methylation and
excretion in clinical trials in Bangladesh. Folate supplementation of folate-deficient
individuals resulted in a 14% decrease in arsenicals in the blood. This is confirmed by
the model and the model predicts that arsenicals in the liver will decrease by 19% and
arsenicals in other body stores by 26% in these same individuals. In addition, the
model predicts that arsenic methyltransferase has been upregulated by a factor of two
in this population. Finally, we also show that a modification of the model gives
excellent fits to the data on arsenic metabolism in human cultured hepatocytes.
Conclusions: The analysis of the Bangladesh data using the model suggests that
folate supplementation may be more effective at reducing whole body arsenic than
previously expected. There is almost no data on the upregulation of arsenic
methyltransferase in populations chronically exposed to arsenic. Our model predicts
upregulation by a factor of two in the Bangladesh population studied. This prediction
should be verified since it could have important public health consequences both for
treatment strategies and for setting appropriate limits on arsenic in drinking water. Our
model has compartments for the binding of arsenicals to proteins inside of cells and
we show that these comparments are necessary to obtain good fits to data. Protein-
binding of arsenicals should be explored in future biochemical studies.
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Arsenic in drinking water is a major health hazard to millions of people in South and
East Asia and in other parts of the world [1,2]. Long term arsenic exposure has been
linked to cancer, heart disease, neuropathies and neurological sequelae, and to deficits
in intelligence in children [3,4]. Arsenic in water is normally ingested primarily as tri-
valent inorganic arsenic (iAs), which then undergoes hepatic methylation to methylar-
sonic acid (MMAs) and a second methylation to dimethylarsinic acid (DMAs). Each
step involves a reduction from pentavalent to trivalent form. While the intermediate
trivalent form of MMA is known to be highly toxic [5-7], the pentavalent form,
DMA
V, is more readily excreted in urine and facilitates elimination of As. This is evi-
dent in AS3MT deficient mice which demonstrate substantially higher As retention in
tissues [8].
The purpose of our collaborative project between epidemiologists and mathematical
modelers is to investigate, through modeling, various proposed nutritional supplements
that could increase the speed of arsenic methylation in hepatic cells. S-adenosylmethio-
nine (SAM), a metabolite of methionine, is the universal methyl group donor. The SAM
concentration is influenced by the folate cycle and the rest of one-carbon metabolism
via the methionine synthase reaction that remethylates homocysteine to methionine. It
is known both from experimentation [9] and from modeling [10] that an increase in
folate status increases the concentration of SAM in hepatic cells. Thus one might predict
that increasing folate status would increase the rate of methylation of iAs and this has
been verified for folate-deficient individuals in Bangladesh [11,12]. Other proposed sup-
plements are the products of other methylation pathways that might cause those path-
ways to be down regulated leaving more methyl groups available for methylating arsenic.
Since the biochemical pathways are complex, highly regulated, and interconnected, it is
not easy to guess what the results of such supplementation will be.
Because iAs and its methylated metabolites, MMAs and DMAs, are not measured in
the livers of human subjects but in blood and in urine, it is important to have a whole
body model that connects arsenic metabolism in the liver to the blood and urine con-
centrations of iAs, MMAs, and DMAs. This paper presents such a model (Figure 1).
We chose the parameters for the methylation reactions from the biochemical literature
and adjusted the transport parameters so that the model accurately predicts the single
dose experiments in [13]. Necessarily the model contains various simplifications of the
complex biochemical processes by which various arsenicals are transported between
compartments and methylated and stored in human livers. We describe some of these
simplifications in the Discussion.
We use the model to explore three different data sets. First we show that the model,
with no changes of parameters gives excellent fits to the time courses of urine excre-
tion of the arsenic metabolites in the multiple dose experiments in [14]. Second, we
study the extensive data of Gamble et al. [11,12] who showed that folate supplementa-
tion of folate-deficient individuals in Bangladesh increases DMA in urine and decreases
total blood arsenic by 14%. The model confirms the 14% decrease in the blood. In
addition the model predicts two other consequences (not measured in Bangladesh) of
folate supplementation: (1) that liver arsenicals decrease by 19% and (2) other body
stores decrease by 26%. In addition, the model predicts that arsenic methyltranferase
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which are the main results of our modeling, should be tested experimentally. Third, we
show that, with some changes of parameters, the model gives good fits to experiments
on human cultured hepatocytes.
There are a number of other pharmacokinetic models of whole body arsenic storage
and methylation. Mann et al. [15] created a whole body model with many tissue com-
partments for hamsters and rabbits and then extended the model for use with human
data [16]. Further work by this group created a whole body model for mice [17]. The
model by Yu et al. [18] was used to make predictions but was not compared to experi-
mental data. Kenyon et al. [19], and Easterling et al. [20], created detailed models for
methylation and transport into and out of hepatocytes so that they could be used to
understand the cell culture experiments in [21] on rat and human hepatocytes. And,
finally, El-Marsi et al. [22] extended this model to the whole body case. Each of these
models treats methylation somewhat differently than we do and differently from each
other.
II. Methods
A schematic diagram of the model is given in Figure 1. All of the indicated transport
velocities and reactions are assumed to have linear dependence on their substrates
except for the two methylation reactions. The full names of the variables in the model
are indicated in Table 1 and the differential equations satisfied by the variables are
Figure 1 A schematic description of the model. Rate constants, abbreviations, differential equations, and
difficult modeling issues are discussed in Methods.
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ential equations we discuss the main modeling issues.
d[gut]
dt
= input(t) − k1[gut]
d[BiAs]
dt
= k1rgb[gut] + k−2rsb[bodystore] + k−3rlb[LiAs] − (k3 + k2 + k6)[BiAs]
d[BMMAs]
dt
= k−4rlb[LMMAs] − (k−4 + k7)[BMMAs]
d[BDMAs]
dt
= k−5rlb[LDMAs] − (k5 + k8)[BDMAs]
d[bodystore]
dt
= k2r−1
sb [BiAs] − k−2[bodystore]
d[LiAs]
dt
= k3r
−1
lb [BiAs] − k−3[LiAs] + k−9[LiAs − store] − k9[LiAs] − V1([LiAs], [LMMAs])
d[LiAs − store]
dt
= k9[LiAs] − k−9[LiAs - store]
d[LMMAs]
dt
= k4r
−1
lb [BMMAs] − k−4[LMMAs] + V1([LiAs], [LMMAs]) − V2([LiAs], [LMMAs])
d[LDMAs]
dt
= k5r−1
lb [BDMAs] − k−5[LDMAs] + V2([LiAs], [LMMAs]) + k−10[LDMAs − store] − k10[LDMAs]
d[LDMAs − store]
dt
= k10[LDMAs] − k−10[LDMAs − store]
d[UiAs]
dt
=3 k6[BiAs]
d[UMMAs]
dt
=3 k7[BMMAs]
d[UDMAs]
dt
=3 k8[BDMAs]
Table 1 Variables in the Model (μM)
gut inorganic arsenic in the gut
BiAs blood inorganic arsenic
BMMAs blood monomethyl arsenic
BDMAs blood dimethyl arsenic
bodystor storage of inorganic arsenic in non-liver tissues
LiAs liver inorganic arsenic
LiAs-stor liver storage of inorganic arsenic
LMMAs liver monomethyl arsenic
LDMAs liver dimethyl arsenic
LDMAs-stor liver storage of dimethyl arsenic
UiAs urinary inorganic arsenic
UMMAs urinary monomethyl arsenic
UDMAs urinary dimethyl arsenic
Table 2 Constants*.
gut = 1 blood = 3 liver = 2 store = 30 volumes (liters)
rgb = 1
3 rsb =1 0 rlb = 2
3 volume ratios
k1 = .11 k2 =. 9 k-2 = .01 gut to blood, blood to body store (hr
-1)
k3 =7 k-3 =1 k9 =. 1 k-9 = .01 iAs, blood to liver, liver to liver store (hr
-1)
k4 =. 1 k-4 = .1 MMAs, blood to liver (hr
-1)
k5 =. 2 k-5 =. 1 k10 =. 1 k-10 = .1 DMAs, blood to liver, liver to liver store (hr
-1)
k6 = .253 k7 = .17 k8 = .85 iAs, MMAs, DMAs, blood to urine (hr
-1)
Km = 4.6 Vmax =. 7 KiAs
i =4 0 KMMA
i =1 . 2 6 methylation, iAs ® MMAs (μMo rμM/hr)
Km =3 Vmax =. 7 KiAs
i =4 0 methylation, MMAs ® DMAs (μMo rμM/hr)
* for definition of the rate constants see Figure 1 and the text.
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The velocity of the first methylation step, V1, is given by
V1 =
Vmax[LiAs]
(Km +[ LiAs])(1 +
[LiAs]
Ksi )(1 +
[LMMAs]
Ki )
(1)
We take the value of the Michaelis-Menten constant Km =4 . 6μM for arsenic (+3 oxida-
tion state) methyltransferase (AS3MT) from [23]. This reaction shows substrate inhibition
by LiAs as well as inhibition by the product LMMAs. We take the substrate inhibition
constant Ksi =1 . 2 6μM from [24]. While product inhibition of the AS3MT enzyme is
known to occur, Ki values are not currently available, so we choose Ki =4 0μMf o rt h e
enzyme described in [25]. We note that different methyltransferases have been identified
in different species [26]. For the second methylation step, V2, we use the formula
V2 =
Vmax[MMAs]
(Km +[ MMAs])(1 +
[LiAs]
Ki )
. (2)
We chose the Km = 4.6 μM as for the first step. This reaction from LMMAs to LDMAs
is also inhibited by LiAs and we choose the inhibition constant to be Ki =4 0μMf r o m
[25]. The value of Vmax =1μM/hr for both reactions was chosen by fitting the Buchet
data (see below).
IIB. Storage Compartments
Since we are not focusing on the distribution of arsenic compounds in different body
tissues, our model has only a single whole-body storage compartment that represents
all the non-liver tissues. Arsenic compounds are measured in units of μMi nt h e
model so the volumes of compartments are important because the ratios of volumes
appear in the differential equations when arsenic compounds are transported from one
compartment to another. The volumes assumed and their ratios are give in Table 2.
We include in our model a liver storage compartment for iAs and a liver storage com-
partment for DMAs because we found that including such compartments was necessary
to obtain excellent fits to data. There are many reasons to believe that arsenic com-
pounds bind to proteins in the liver; in fact, such binding is one of the likely modes of
arsenic toxicity [27,28]. These bound arsenicals are not available for methylation. The
models in [19] and [20] also used liver storage compartments for arsenic compounds in
their pharmacokinetic models for the in vitro experiments in [21]. We found that includ-
ing a compartment for MMAs liver storage was not necessary to obtain excellent fits to
the data. Thus, in order to keep our model as simple as possible, we did not include
such a compartment, even though there surely is some binding of MMAs to proteins.
IIC. Arsenic input
We assume that single oral doses of arsenic become available in the gut over a six
minute period and are then transported with linear kinetics (k1)i n t ot h eb l o o d .T h e
value of k1 = .11/hr listed in Table 2 is the transport rate of arsenic trioxide, which is
the usual compound that is dosed. In the MMAs and DMAs dosing experiments
described below, k1 is changed to 2/hr and .125/hr respectively. There is evidence that
the different arsenic metabolites are transported at different rates from the gut to the
blood [29], and these different values appeared naturally when we fit the data in
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Buchet et al. [13]. For the discussion of chronic exposure and the Gamble data in the
R e s u l t sS e c t i o n ,w et a k et h ei n p u tt ot h eg u tt ob ec o n s t a n ts ot h a tt h et o t a ld a i l y
input is 300 μg.
IID. Arsenic output
Notice that the differential equations for the urinary metabolites, UiAs, UMMAs,
UDMAs, have an extra factor of 3, which is the assumed volume of the blood plasma
in liters. Thus, unlike the other variables in the model, the urinary variables are in
micromoles rather than micromolar so that we can easily compare to data. To obtain
the model data points at the end of each time interval, we accumulate each of the
arsenic species in the urine since the previous data point and then divide by the time
between data points to get a rate of excretion to compare to the measured rates in
urine.
IIE. Tuning of parameters
In the experiments of Buchet et al. [13], a 500 μg dose of iAs was given and the time
courses of iAs, MMAs, and DMAs in the urine were measured. In a separate experi-
ment, a 500 μg dose of MMA was given and the time courses of MMAs and DMAs in
the urine was followed. Finally, a 500 μg dose of DMAs was given and the time course
of DMAs in the urine were followed. We exploited this wealth of data as follows. First
we considered just the DMAs experiment, since only the parameters k5, k-5, k10, k-10,
k8 and rate from gut to blood are involved. After tuning these parameters to get the
experimental DMAs output curve, we then considered the MMAs experiment. Here
five new parameters were involved, k4, k-4, k7, the Vmax of the second methylation step,
and the rate of MMAs transfer from gut to blood. After tuning these parameters to
obtain the MMAs and DMAs output curves in this case, we then considered the full
model with iAs input and compared to the output curves for iAs, MMAs, and DMAs.
After we tuned the parameters, the model gave excellent fits, both quantitatively and
qualitatively, to the iAs experiments, the MMAs experiments, and the DMAs experi-
ments for single doses reported in Buchet et al. [13] over the full 100 hour time course.
It is known that individuals show large variation in their ability to methylate arsenic
[30,31]. The experimental data shown in Figure 2 consists of averages over only 3 indivi-
duals (iAs or MMAs) or four individuals (DMAs). Thus one would not expect perfect
fits for any model. Below, we use the model, validated for the Buchet et al. [13] single
dose experiments, to explore its fit to other experimental studies.
III. Results
First we compare model predictions with the repeated dose experiments in Buchet et
al. [14]. Next, we use the model to study and interpret the data obtained by Gamble et
al. [11,12] who measured blood and urine arsenic levels in the Bangladesh population
both with and without folate supplementation. Finally, we show that using the same
model, but with different parameters, we can match the in vitro experiments in [21].
IIIA. Data from repeated dose experiments
In the multiple dose experiments of Buchet et al. [14], four volunteers were given five
daily doses of arsenic at the levels 125 μg, 250 μg, 500 μg, and 1000 μg, respectively.
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arsenic, MMAs, and DMAs were measured. These amounts were divided by the num-
ber of hours since the last sample to obtain a current rate of metabolite excretion in
μmole/hr at each time point. The results are indicated by the grey dots in Figure 3,
where the four rows correspond to the doses of 125 μg, 250 μg, 500 μg, and 1000 μg
respectively and the columns are the excretion rates for inorganic arsenic, MMAs,
DMAs, and total arsenic respectively. In each case the blue dots show the excretion
rates produced by our mathematical model using the set of parameters determined by
fitting the single dose data in Buchet et al. [13], as described in Methods. No para-
meters were changed in any of the 12 model experiments shown in Figure 3. Note that
the scales on the y axes differ in the different panels of Figure 3.
The model predictions of the time courses of excretion rates are quite close to the
experimentally observed time courses, except for two cases. The first methylation step
was quite a bit faster for the volunteer who received the 250 μg dose than the model
predicts. And, the second methylation step was slower for the volunteer who received
the 1000 μg dose than the model predicts. In all four cases, the match to the time
course of total arsenic excretion was excellent. It should be pointed out that the
experimental results in each row are measurements for a single individual and it is
well known that individuals can differ significantly in their arsenic storage and methy-
lation capacities. Thus it is remarkable that our simple model, with the same choice of
parameters, fits the data so well for all four individuals who received different repeated
doses (Figure 3) as well as those receiving a single dose (Figure 2).
Figure 2 Fits of model results to the single dose data in Buchet et al. [13]. Model results are given in
blue, experimental data in grey (micromoles/hr in the urine). In the first row volunteers were given 500 μg
of inorganic arsenic. In the second row they were given 500 μg of MMAs. In the third row they were given
500 μg of DMAs.
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compartments for iAs and DMAs in the liver. In all cases in Figure 3 the concentration
of inorganic arsenic drops rapidly after the fifth and final dose, and then has a long flat
tail, as do the concentrations of MMAs and DMAs. This suggests that free arsenic is
quite rapidly methylated and cleared and that the long flat tails correspond to slow
leakage of arsenic from storage compartments. But is this storage in extrahepatic tis-
sues or in liver cells? It is difficult to tell from the urine excretion rates in Figure 3.
However, the in vitro data [21] on human liver cells have similar long flat tails suggest-
ing that there is storage in the liver cells. In fact, there is strong experimental evidence
in [27] and [28] that arsenicals bind substantially to proteins. Liver storage compart-
ments for arsenic compounds were used by Kenyon [19] and Easterling [20] in model-
ing the human hepatocyte data [21]. We experimented with all possible combinations
of storage compartments, body storage, and liver storage for iAs, MMAs, and DMAs.
We found that to get good fits to the data that we used to tune the model (Figure 2),
we needed both the body storage of iAs and the storage of iAs and DMAs in the liver
cells. If any one of these storage compartments is omitted, the model predictions differ
considerably from the data. We found that we did not need a storage compartment for
MMAs in order to obtain excellent fits to the data, so we did not include it in the
model, even though it is likely there is some binding of MMAs to liver proteins also.
Figure 3 Comparison of model results to the repeated dose experiments in Buchet et al. [14].
Model results are given in blue, experimental data in grey (micromoles/hr in the urine). In the first, second,
third, and fourth rows, volunteers were given 5 daily doses of 125 μg, 250 μg, 500 μg, 1000 μg, of
inorganic arsenic, respectively. The four columns show the time courses of inorganic arsenic, MMAs, DMAs,
and total arsenic in the urine, respectively, over 14 days.
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of 500 μg daily) with the storage compartments removed. Note that the model curves
go to zero before 200 hours while the data have long flat tails.
IIIB. The effect of folate supplementation on arsenic methylation
Gamble et al. [11,12] have shown that folate supplementation of folate-deficient indivi-
duals in Bangladesh significantly increased arsenic methylation and decreased total blood
arsenic. The ap r i o r ihypothesis of Gamble was that the mechanism is as follows: 5-
methyltetrahydrofolate is a substrate for the methionine synthase reaction through which
homocysteine is remethylated to methionine that is then converted to S-adenosylmethio-
nine (SAM). Thus one would expect the SAM concentration to be positively correlated
with the folate status of the individual and, indeed, a correlation coefficient of 0.74
between serum folate and liver SAM was reported in [32]. Reed et al. [10] showed, using a
mathematical model of folate and methionine metabolism, that SAM concentration (as
percent of normal) in liver cells is a linear function of liver total folate (as percent of nor-
mal) with a slope of about 0.9. A later more comprehensive mathematical model,
described in [33], gives a similar result but the slope is computed to be 1 (unpublished).
One would thus expect that folate supplementation would increase SAM in folate-defi-
cient individuals. SAM is the universal methyl donor in liver cells, so as SAM concentra-
tion rises more methyl groups should become available for AS3MT. Folate
supplementation should increase the percentage of arsenic in the DMAs form and, since
DMAs is excreted more rapidly than MMAs or iAs, one would expect the rate of arsenic
excretion to rise. The purpose here is to make quantitative calculations about these effects
and to compare the model predictions with the results measured by Gamble et al. [11,12]
in Bangladesh. Another part of Gamble’s hypothesis is that folate supplementation should
lower SAH and thus lower the inhibition of AS3MT, but this hypothesis is not tested here.
In the definitions of V1 and V2 in the Methods we assumed that the concentration of
SAM was constant and the effect of SAM was included in Vmax. We now make the
dependence on SAM explicit:
V1 =
Vmαx[LiAs]
(Km +[ LiAs])(1 +
[LiAs]
Ksi )(1 +
[LMMA]
Ki )

α[SAM]
Km +[ SAM]

V2 =
Vmαx[MMA]
(Km +[ MMA])(1 +
[LiAs]
Ki )

α[SAM]
Km +[ SAM]

.
Figure 4 The storage compartments are necessary. Model results are given in blue, experimental data
in grey (micromoles/hr in the urine). If all storage compartments are removed, the model predictions differ
considerably from the data in Buchet et. al., 1981a, for the experiments with a 500 μg dose of iAs.
Compare to row 1 in Figure 2 where the model includes all three storage compartments.
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that the last factor is equal to one when SAM has a “normal” concentration. Thus the
methylation reactions are as described in the Methods when SAM is normal (corre-
sponding to the folate supplemented population) but will be slower when SAM is
below normal (corresponding to the folate-deficient population before supplementa-
tion). We remark that, for simplicity, we are leaving out the inhibition of the methyl
transferase reactions by S-adenosylhomocysteine and the homeostatic effects of the
long-range inhibitions discussed in Nijhout et al. [34].
Unfortunately, measurements of liver SAM in the folate supplemented and folate-
deficient populations are not available, so we must estimate them from other studies.
The classical studies of Finklestein [35,36] found a mean liver SAM concentration of
83.6 μM in rats and a range of 60-160 μM on different diets. On the other hand, Sel-
hub [37] found SAM concentrations in human livers to be in the range 20 - 60 μM. In
our previous modeling studies, where necessarily most of the parameters are deter-
mined from rat data, we have often assumed that liver SAM is 60 μM. If we assume
that “normal” SAM is 60 μM, then the constant a = 1.1967. If we assume that “nor-
mal” SAM is 40 μM, then the constant a = 1.2950. Below we argue that liver SAM in
the folate-deficient population should be about 1
4 of normal. The results described
below are not very different if we assume normal SAM is 60 μM and folate-deficient
SAM is 15 μM or if we assume normal SAM is 40 μM and folate-deficient SAM is 10
μM. So we will choose SAM = 60 μM and a = 1.1967.
The next question is how to estimate liver SAM in the folate-deficient population.
Gamble et al. [11] studied 194 folate-deficient individuals in Bangladesh; their mean
plasma folate was approximately 8 nmol/L. Pfeiffer et al. [38] found a mean folate level
in the U.S. population (after folate fortification) of approximately 32 nmol/L in plasma.
So, the folate-deficient group studied by Gamble et al. had only 1/4 the observed
serum folate concentration found in the U.S. after fortification. Clifford et al. [39]
show that serum and liver folate are highly correlated and that when serum folate goes
up by a factor of 3, liver folate goes up by a factor of 2.5. In addition, Min et al. [32]
show that when liver folate goes up by a factor of 3.5, then liver SAM also goes up by
a factor of approximately 3.5. This is consistent with our modeling studies in which we
found that SAM concentration (as percent of normal) in liver cells is a linear function
of total liver folate (as percent of normal) with a slope of 0.9.-1. Taken together, these
studies suggest that, in the physiological range, it is reasonable to assume that liver
SAM increases proportionally to serum folate with a slope of about one. Thus since
the folate-deficient group in Bangladesh had only 1
4 normal folate, we estimate that
they also had approximately 1
4 normal SAM.
The Bangladesh population has been continuously exposed to arsenic in drinking
water and it would be reasonable to assume that their average expression levels of
AS3MT are substantially higher than those of the Belgian volunteers [13] on which the
model was tuned in the Methods Section. Unfortunately, there are no data to support
this assumption and no way of directly comparing the AS3MT expression levels in the
two groups. There are data that suggest a modest increase in AS3MT expression in
rats after exposure to arsenic in drinking water [40] and in [41] it is suggested that the
high percentage of DMAs in the urine of a population exposed to high levels of arsenic
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vary widely within and between human populations [31,30]. These large differences
likely depend on genetic background, nutritional status, and environmental exposure
and it is difficult to determine how to untangle these causes without more human
genetic studies. Therefore, we experimented with the model to see what increase in
AS3MT (corresponding to an increase of Vmax) in the methylation reactions would
give the mean blood levels of the arsenic metabolites and the mean arsenic excretion
profiles observed by Gamble et. al. [11,12] in the folate-deficient Bangladesh popula-
tion. We found that doubling the AS3MT expression level gave an almost perfect fit to
the Gamble data before supplementation (Table 3).
To summarize, we modified the model described in the Methods as follows. We
included explicitly the dependence of the methylation reactions on SAM and chose a
so that the new factor in equations (1) and (2) equals one if SAM concentration is nor-
mal. To obtain the profile of the folate-deficient Bangladesh population, we lowered
SAM from 60 μMt o1 5μM and we doubled Vmax from 1 μM/hr to 2 μM/hr. There-
fore the methylation reactions are as given in equations (3) and (4) below. All other
parameters are identical to those in the Methods.
V1 =
2Vmαx[LiAs]
(Km +[ LiAs])(1 +
[LiAs]
Ksi )(1 +
[LMMAs]
Ki )

15α
Km +1 5

(3)
V2 =
2Vmαx[MMAs]
(Km +[ MMAs])(1 +
[LiAs]
Ki )

15α
Km +1 5

. (4)
Table 3 shows that the model percentages of the arsenicals in the blood and in the
urine correspond very closely to those reported by Gamble et al. ([12], their Figure 3)
for the folate-deficient population before supplementation.
Gamble et al. [11,12] measured the arsenicals in the blood and urine after 12 weeks
of folate supplementation (400 μg/day). In the model, we represent the result of folate
supplementation by returning the value of [SAM] from 15 μM to the normal value of
60 μM. Table 4 compares the model results with those observed by Gamble et al.
[11,12].
Folate supplementation not only shifted the balance of arsenicals towards DMA in
the blood and the urine, it also reduced the total arsenic in the blood (by 14% in Ban-
gladesh population and by 13% in the model). After folate supplementation, the per-
centages of the urinary metabolites are very similar in the model and the Gamble data.
It is particularly interesting that total liver arsenic (free plus storage) drops by 19% in
the model after folate supplementation and that the body store drops by 26% in the
model after folate supplementation. These are quantities that could not be measured
Table 3 Measured and model percentages of arsenicals for the Bangladesh folate-
deficient population before folate supplementation
inorganic As MMAs DMAs
blood (Gamble) 26% 40% 34%
blood (model) 26% 39% 35%
urine (Gamble) 15% 13% 72%
urine (model) 15% 15% 69%
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folate-deficient population may have even greater health benefits than are suggested by
the measured 14% drop in blood arsenic. Other model results (not shown) also mimic
the clinical results. For example, urinary DMAs increases substantially after one week
of supplementation before descending to a more modest increase from baseline at 12
weeks. Therefore, the model gives strong support to the hypothesis that folate supple-
mentation is helpful for the folate-deficient population because increasing folate
increases SAM dramatically for those individuals. Since their SAM concentrations are
relatively low (near the Km of SAM for AS3MT) increasing SAM has a large effect on
the rate of methylation. It is not entirely clear that folate supplementation would
increase methylation of arsenic for a folate-sufficient population because higher than
normal SAM concentrations are well over the Km of SAM, so the methylation reac-
tions are already saturated. However, folate supplementation might also lower SAH,
which would release some of the inhibition of AS3MT and therefore increase
methylation.
IIIC. Arsenic exposure in human hepatocytes
The dynamic behavior of all three arsenicals, iAs, MMAs, and DMAs have been studied
in in vitro experiments with cultured rat and human hepatocytes [21]. Therefore it was
of interest to see whether a modification of our model corresponding to their experi-
mental conditions would give predictions that were close to the experimental curves.
We modified the model by eliminating the urine compartment, input from the gut,
and body storage. The word “blood” is now replaced in Figure 1 by the word “medium”
and the word “liver” is replaced by the word “cells.” The differential equations are the
same as those given in the Methods except that many of the rate constants (k1, k6, k7, k8,
k10, k-10) are now equal to 0. In addition, rcm replaces rlb. There is no body store but we
do have storage in the medium (see below) between free and bound iAs (rate constants
k2 and k-2) and this means that rsb = 1. The constants are indicated in Table 5.
We include storage in the cells for iAs as we did in the full model but we didn’t need
storage of DMAs in the cells. We include storage in the medium because the collagen
coated well plates used by [21] are likely to bind iAs because of the sulphur groups on
collagen. We note that the model in [20] uses cell storage for iAs as we do. The Styblo
wells had a volume of 0.5 ml and there were approximately (.25) × 10
6 cells in each
culture. Assuming each cell has volume 2 × 10
-9, which is reasonable, then the volume
of cells is 0.0005 ml and the volume ratio of cells to medium is 0.001.
We note that the rate constants in Table 5 are somewhat different from the rate
constants in Table 2. This is not surprising since transport between the medium and
Table 4 Measured and model percentages of arsenicals for the Bangladesh folate-
deficient population after 12 weeks of folate supplementation
inorganic As MMAs DMAs total (% change)
blood (Gamble) 23% 37% 40% -14%
blood (model) 22% 33% 45% -13%
urine (Gamble) 10% 11% 79%
urine (model) 11% 11% 77%
liver (model) -19%
body-stor (model) -26%
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liver, the medium store and the body store are different, and the cultured cells are
likely to be different from hepatocytes in whole liver. However, the Km and the Ki
values are the same.
In the experiments in [21], arsenic was introduced into the medium at t = 0 and the
times courses of iAs, MMAs, DMAs, and total arsenic in the medium and in the cells
were measured. The grey dots in Figure 5 are the experimental values for an initial
arsenic concentration of 0.1 μM. The blue dots are the model predictions and match
the experimental points well. In particular they capture the convex and concave shapes
of total arsenic curves in the cells and the medium.
IV. Discussion
We have developed a relatively simple mathematical model for arsenic storage, methy-
lation, and excretion into the urine (Figure 1). We lumped all non-liver body storage
compartments together because our main interest is methylation in the liver and the
dynamics of urinary excretion. All transport, excretion, and storage reactions are linear
Table 5 Constants for the reduced model containing medium and cells
medium = 0.5 cells = 0.0005 rcm = 0.001 volumes (ml), volume ratio
k2 = 0.4 k-2 = .07 iAs, medium to medium store (hr
-1)
k3 = 0.45 k-3 = 0.5 k9 = 0.3 k-9 = 0.05 iAs, medium to cells, cell to cell store (hr
-1)
k4 = 0.2 k-4 = 0.05 MMAs, medium to cells (hr
-1)
k5 = 0.015 k-5 = 0.2 DMAs, medium to cells (hr
-1)
Km = 4.6 Vmax =2 2 KiAs
i =4 0 KMMA
i =1 . 2 6 methylation, iAs® MMAs (μMo rμM/hr)
Km = 4.6 Vmax = 2.75 KiAs
i =4 0 methylation, MMAs ® DMAs (μMo rμM/hr)
Figure 5 Comparison of model predictions to data on human hepatocytes. Experimental data points
are in grey, model predictions are in blue. 0.1 μM was introduced into the medium at t = 0. The data
from Figure 1 of Styblo et al. [21], has been converted into micromolar.
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Page 13 of 17in the model, but the methylation reactions in the liver are Michaelis-Menten (includ-
ing inhibition) and are based on experimental measurements of Km and Ki values. The
other parameters were systematically tunedb yu s i n gt h ed a t ao ni n g e s t i o no fs i n g l e
doses of DMAs, MMAs, and iAs in Buchet et al. [13], and excellent fits to the data
were obtained (Figure 2). We remark that many previous whole body models of arsenic
metabolism (discussed in the Introduction) try to fit the functions that give the cumu-
lative amounts of iAs, MMAs, and DMAs in the urine, while we fit the rates of excre-
tion. We do this for three reasons. First, the data itself come as amount excreted in a
time period, i.e. a rate. Second, it is much easier to fit the cumulative curves since
both the data and the model curves will be increasing and saturate. It is much more
difficult to fit the rate curves, and thus fitting the rate curves is a more stringent test
of the model. Finally, there is information in the rate curves that it hard to see in the
cumulative curves; for example, the rate curves show long, flat tails indicative of slow
leakage out of storage compartments.
Various aspects of the biochemistry of arsenic metabolism have been greatly simpli-
fied in this whole body model. We assume that aresenic is ingested as arsenic trioxide;
in fact, relatively small amounts of other forms of arsenic are also ingested. We ignore
completely the reduction steps from pentavalent forms to trivalent forms in the liver
that use glutathione. And, finally, we ignore many of the complex regulatory mechan-
isms in one-carbon metabolism that affect methylation, such as the inhibition of the
methylation reactions by S-adenosylhomocysteine and the inhibition of glycine methyl-
tranferase by 5-methyltetrahydrofolate. The fact that our model fits three different sets
of data so well suggests that these simplifications are reasonable in a whole body
model. In future work on competing methylation pathways the full details of the bio-
chemistry will be included.
In Section IIIA, we compared the predictions of the model (with no changes of para-
meters) to the multiple dose experiments in Buchet et al. [14]. The model predictions
correspond very well to the experimental urine excretion curves at all four dose levels
(Figure 3). A feature of our model is the use of storage compartments in the liver cor-
responding to the reversible binding of arsenicals to proteins. The experimental urine
excretion rates in Figures 2 and 3 drop rapidly after the dose or final dose but then
have long flat tails, particularly for iAs and DMAs. This suggests that free arsenic is
quite rapidly methylated and excreted and that the long flat tails are due to the slow
leakage of arsenicals from storage compartments. This idea is not new; Kenyon et al.
[19] and Easterling et al. [20] used liver storage compartments in their simulations of
the in vitro data in [21]. We assumed liver storage for iAs and DMAs, but not for
MMAs, since we did not need storage of MMAs to get good fits to and predictions of
the data. Figure 4 shows what our model predictions of the Buchet et al. single dose
data [13] would be if all storage compartments were removed. The fit is poor, to say
the least. We experimented with all possible combinations of body storage and liver
storage and found that we needed both liver stores and the body store to get good fits
and predictions.
In Section IIIB we compared model predictions to the measurements of Gamble et.
al. [11,12] of the effects of folate supplementation on the blood and urine levels of
arsenicals in a Bangladesh population of folate-deficient individuals. All parameters in
the model remained the same except that we had to include explicitly the dependence
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about how folate-deficient the population was. Details and justifications of these
assumptions are given in IIIB. The model predictions correspond very closely to the
Gamble measurements of all three arsenicals in the blood and in the urine both before
and after folate supplementation. The model predicts a drop in total blood arsenic
after supplementation of 13% while a dropo f1 4 %w a sm e a s u r e db yG a m b l ee ta l . ,
2007. In addition, the model predicts a drop in total arsenic in the liver of 19% and a
drop in body storage of 26%. These quantities could not be measured, of course, in the
population. Thus the model suggests that the health benefits of folate supplementation
might be even greater than those suggested by the 14% drop in measured blood
arsenicals.
O n ei n t e r e s t i n gr e s u l to fo u ra n a l y s i si st h a tt of i tt h eG a m b l ed a t aw eh a dt o
increase the Vmax of the methylation reactions by a factor of two. This suggests
strongly that arsenic methyltransferase is upregulated by a factor of two in the Bangla-
desh population studied as compared to the Belgian volunteers in the Buchet studies.
Methylation rates vary widely within and between human populations [31,30] and
these large differences likely depend on genetic background, nutritional status, and
environmental exposure. Determining the causal influence of these factors on methyla-
tion is important for designing intervention strategies. This will likely require more
human genetic studies, more population-based studies relating nutritional status to
methylation capacity, and more modeling studies to assist in generating hypotheses
and in the interpretation of data.
Supplementation with vitaminB 1 2w i l lr a i s et h er a t eo ft h em e t h i o n i n es y n t h a s e
reaction and therefore should also increase SAM. However, in the randomized con-
trolled trial by Gamble et al. [12], B12-deficient individuals were excluded from the
study cohort, so we do not have data on B12 status from the same population. We
h a v es h o w ni nam o d e l i n gs t u d y[ 1 0 ]t h a tB 12 status has a much smaller effect on
SAM concentration than does folate status. The reason is that in B12-deficient indivi-
duals 5-methyltetrahydrofolate will build up (the methyl trap) driving the methionine
synthase reaction faster and partially compensating for the lack of B12. Consistent with
this explanation is the finding of Selhub [37] that folate deficiency has a much greater
effect on homocysteine concentration than does vitamin B12 deficiency.
In Section IIIC we modified the model by eliminating the urine compartments and
the body storage so we could see if the resulting model would be sufficient to capture
the results of the in vitro experiments of Styblo et al. [21] on human hepatocytes.
With some changes of transport parameters (the Km and Ki values for the methylation
reactions were kept the same), the model predictions were quite close to the Styblo
results (Figure 5).
As described in the Introduction, the goal of our collaborative project is to investigate,
through modeling, various proposed nutritional supplements that could increase the
speed of arsenic methylation in hepatic cells. This will require us to extend our existing
models of one-carbon and glutathione metabolism ([42,10,33]) to include many of the
parallel methylation reactions that use SAM as a substrate. The methyltransferase reac-
tions are all inhibited (with different Ki values) by the product, S-adenosylhomocysteine.
Other elaborate control mechanisms (see [34]) are known to exist. The elucidation of
the control mechanisms (both genetic and metabolic) by which the cell regulates the
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Page 15 of 17balance of flux between the various methyltransferases is an important biological pro-
blem. By understanding this question through mathematical modeling, we hope to be
able to evaluate current proposals and make new proposals for nutritional intervention
strategies for populations exposed to chronic doses of arsenic. The whole body model in
this paper is the first step in our project, since it will enable us to connect the dynamics
of the methylation reactions in the liver to the presence of arsenicals in the blood and
the urine where they are usually measured.
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